Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Insulet Corp Market Cap
Based on ratings from 8 stock analysts, the Insulet Corp stock price is expected to increase by 22.05% in 12 months. This is calculated by using the average 12-month stock price forecast for Insulet Corp. The lowest target is $208.00 and the highest is $270.00. Please note analyst price targets are not guaranteed and could be missed completely.
PODD is a stock in Health Care which has been forecasted to be worth $233.13 as an average. On the higher end, the forecast price is $270.00 USD by ryan zimmerman from BTIG and on the lower end PODD is forecasted to be $208.00 by mathew blackman from Stifel Nicolaus.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| mathew blackman Stifel Nicolaus | Hold | $208.0 | maintained | Feb 5, 2024 |
| matthew o'brien Piper Sandler | Buy | $250.0 | reiterated | Jan 25, 2024 |
| danielle antalffy UBS | Hold | $211.0 | maintained | Jan 22, 2024 |
| marie thibault BTIG | Buy | $270.0 | maintained | Jan 5, 2024 |
| jeff johnson Robert W. Baird | Buy | $238.0 | upgraded | Dec 21, 2023 |
| larry biegelsen Wells Fargo | Buy | $240.0 | maintained | Dec 13, 2023 |
| patrick wood Morgan Stanley | Buy | $234.0 | upgraded | Dec 4, 2023 |
| matt miksic Barclays | Hold | $214.0 | reiterated | Nov 28, 2023 |
| joanne wuensch Citi | Buy | $260.0 | maintained | Nov 6, 2023 |
| matthew taylor Jefferies | Buy | $240.0 | reiterated | Nov 3, 2023 |
| kyle rose Canaccord Genuity | Buy | $175.0 | maintained | Nov 3, 2023 |
| robbie marcus J.P. Morgan | Buy | $190.0 | maintained | Nov 3, 2023 |
| josh jennings TD Cowen | Buy | $264.0 | reiterated | Nov 2, 2023 |
| mike kratky Leerink Partners | Buy | $190.0 | reiterated | Nov 2, 2023 |
| william plovanic Canaccord Genuity | Buy | $355.0 | maintained | Oct 23, 2023 |
| travis steed Bank of America Securities | Buy | $180.0 | maintained | Oct 18, 2023 |
| ryan zimmerman BTIG | Buy | $270.0 | maintained | Oct 16, 2023 |
| jayson bedford Raymond James | Buy | $228.0 | maintained | Sep 15, 2023 |
| robert marcus J.P. Morgan | Buy | $365.0 | maintained | May 5, 2023 |
| cecilia furlong Morgan Stanley | Hold | $343.0 | maintained | May 5, 2023 |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
When did it IPO
2007
Staff Count
2,600
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. James R. Hollingshead Ph.D.
Market Cap
$13.34B
In 2023, PODD generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PODD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
LKQ-USD
$50.04
NBIX-USD
$132.31
INCY-USD
$58.82
FOXA-USD
$29.95
GEN-USD
$21.55
JKHY-USD
$173.1
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
